EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Efficacy and safety of darolutamide in combination with androgen deprivation therapy and docetaxel in European patients from the phase 3 ARASENS trial

Bertrand Tombal, Maha Hussain, Fred Saad, Karim Fizazi, Neal Shore, Evgeny Kopyltsov, Martin Bögemann, Maria J Mendez-Vidal, Natasha Littleton, Shankar Srinivasan, Frank Verholen, Matthew R Smith

European Journal of Cancer · 2026-06 · 240 · 116730

DOI: 10.1016/j.ejca.2026.116730 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cancer, 2026-06. Verfasst von Bertrand Tombal und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Urology, IREC, Cliniques Universitaires Saint Luc, UCLouvain, Brussels, Belgium. Electronic address: bertrand.tombal@saintluc.uclouvain.b…. Hauptthemen laut MEDLINE: Docetaxel, Antineoplastic Combined Chemotherapy Protocols, Prostatic Neoplasms, Androgen Antagonists. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bayer HealthCare Pharmaceuticals Inc, Bayer HealthCare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DocetaxelAntineoplastic Combined Chemotherapy ProtocolsProstatic NeoplasmsAndrogen AntagonistsProstatic Neoplasms, Castration-ResistantHumansMaleAgedEuropeMiddle AgedDouble-Blind MethodAged, 80 and overTreatment OutcomePyrazoles

Stichwörter der Autor:innen

DarolutamideEfficacyEuropean patientsMetastatic hormone-sensitive prostate cancerSafety

Substanzen

DocetaxeldarolutamideAndrogen AntagonistsPyrazoles

Autor:innen und Institutionen

  • Division of Urology, IREC, Cliniques Universitaires Saint Luc, UCLouvain, Brussels, Belgium. Electronic address: bertrand.tombal@saintluc.uclouvain.be.
  • Northwestern University, Feinberg School of Medicine, Chicago, IL, USA.
  • University of Montreal Hospital Center, Montreal, Quebec, Canada.
  • Centre Oscar Lambret, Institut Gustave Roussy, University of Paris-Saclay, Lille, France.
  • START Carolinas/Carolina Urologic Research Center, Myrtle Beach, SC, USA.
  • Clinical Oncological Dispensary of Omsk Region, Omsk, Russian Federation.

Förderung

  • Bayer HealthCare Pharmaceuticals Inc
  • Bayer HealthCare

Zitieren

APA

Tombal, B., Hussain, M., Saad, F., Fizazi, K., Shore, N., Kopyltsov, E., Bögemann, M., Mendez-Vidal, M. J., Littleton, N., Srinivasan, S., Verholen, F., & Smith, M. R. (2026). Efficacy and safety of darolutamide in combination with androgen deprivation therapy and docetaxel in European patients from the phase 3 ARASENS trial. European Journal of Cancer, 240, 116730. https://doi.org/10.1016/j.ejca.2026.116730

Vancouver

Tombal B, Hussain M, Saad F, Fizazi K, Shore N, Kopyltsov E, et al. Efficacy and safety of darolutamide in combination with androgen deprivation therapy and docetaxel in European patients from the phase 3 ARASENS trial. European Journal of Cancer. 2026;240:116730. doi:10.1016/j.ejca.2026.116730

BibTeX
@article{Tombal2026,
  author = {Tombal, Bertrand and Hussain, Maha and Saad, Fred and Fizazi, Karim and Shore, Neal and Kopyltsov, Evgeny and Bögemann, Martin and Mendez-Vidal, Maria J and Littleton, Natasha and Srinivasan, Shankar and Verholen, Frank and Smith, Matthew R},
  title = {Efficacy and safety of darolutamide in combination with androgen deprivation therapy and docetaxel in European patients from the phase 3 ARASENS trial},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {240},
  pages = {116730},
  doi = {10.1016/j.ejca.2026.116730}
}
Kostenlos starten →